Vantrela ER Approval Status
- FDA approved: No
- Brand name: Vantrela ER
- Generic name: hydrocodone bitartrate
- Dosage form: Extended-Release Tablets
- Company: Teva Pharmaceutical Industries Ltd.
- Treatment for: Pain
Vantrela ER (hydrocodone bitartrate) is an abuse deterrent opioid formulation in development for the management of severe pain.
Development Status and FDA Approval Process for Vantrela ER
|Jun 7, 2016||Teva Gains Recommendation for Approval from FDA Advisory Committees for Vantrela ER (hydrocodone bitartrate) Extended-Release Tablets|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.